USD 6.14
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| LFCR | -4.5 | -5.7 | -12.7 | 15.6 | 9.3 | -6.0 | -44.1 | -46.2 | -54.9 | -51.8 |
| S&P 500 | 0.5 | 2.1 | 2.4 | 5.5 | 10.1 | 25.8 | 38.7 | 84.0 | 198.2 | 34547.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | LFCR |
| name | Lifecore Biomedical, Inc. |
| price | 6.14 |
| changes percentage | -4.5101 |
| change | -0.29 |
| day low | 6.05 |
| day high | 6.44 |
| year high | 8.9 |
| year low | 3.68 |
| market cap | 227335342 |
| price avg 50 | 7.0272 |
| price avg 200 | 5.8845 |
| exchange | NASDAQ |
| volume | 183966 |
| avg volume | 252380 |
| open | 6.35 |
| previous close | 6.43 |
| eps | -0.56 |
| pe | -10.96 |
| earnings announcement | 2025-04-02T12:00:00.000+0000 |
| shares outstanding | 37025300 |
| timestamp | 2025-01-23 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001005286 | |||
| revenue | 128261000 | 103269000 | 24.20 |
| gross profit | 41850000 | 27292000 | 53.34 |
| gross profit ratio | 0.33 | 0.26 | 23.46 |
| research and development expenses | 8575000 | 8240000 | 4.07 |
| operating expenses | 49038000 | 51258000 | -4.33 |
| interest income | 0 | 68000 | -100.00 |
| interest expense | 18090000 | 18184000 | -0.52 |
| ebitda | 35604000 | -35979000 | 198.96 |
| ebitdaratio | 0.28 | -0.11 | 357.82 |
| operating income | 9331000 | -26083000 | 135.77 |
| operating income ratio | 0.07 | -0.25 | 128.80 |
| net income | 12013000 | -102190000 | 111.76 |
| net income ratio | 0.09 | -0.99 | 109.46 |
| eps | 0.39 | -3.41 | 111.44 |
Revenue Growth: revenue increased to 128 million in 2024 from 103 million in 2023 representing a change of 24.2%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 42 million in 2024 from 27 million in 2023 representing a change of 53.34%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 9 million in 2024 from 8 million in 2023 representing a change of 4.07%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Expenses: Operating Expenses decreased to 49 million in 2024 from 51 million in 2023 representing a change of -4.33%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 36 million in 2024 from -36 million in 2023 representing a change of 198.96%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to 9 million in 2024 from -26 million in 2023 representing a change of 135.77%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 12 million in 2024 from -102 million in 2023 representing a change of 111.76%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 0.39 in 2024 from 0.39 in 2023 representing a change of 111.44%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2025Q2 | 2025Q1 | Q/Q change % | |
|---|---|---|---|
| 0001005286 | |||
| revenue | 32564000 | 24705000 | 31.81 |
| gross profit | 11084000 | 5387000 | 105.75 |
| gross profit ratio | 0.34 | 0.22 | 56.10 |
| research and development expenses | 1924000 | 2186000 | -11.99 |
| operating expenses | 13043000 | 16971000 | -23.15 |
| interest income | 0 | 0 | NaN |
| interest expense | 5465000 | 5368000 | 1.81 |
| ebitda | 981000 | -8894000 | 111.03 |
| ebitdaratio | 0.03 | -0.36 | 108.37 |
| operating income | -1959000 | -11584000 | 83.09 |
| operating income ratio | -0.06 | -0.47 | 87.17 |
| net income | -6571000 | -16230000 | 59.51 |
| net income ratio | -0.2 | -0.66 | 69.28 |
| eps | -0.25 | -0.53 | 52.83 |
Revenue Growth: revenue increased to 33 million in 2025Q2 from 25 million in 2025Q1 representing a change of 31.81%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 11 million in 2025Q2 from 5 million in 2025Q1 representing a change of 105.75%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 13 million in 2025Q2 from 17 million in 2025Q1 representing a change of -23.15%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to 1 million in 2025Q2 from -9 million in 2025Q1 representing a change of 111.03%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -2 million in 2025Q2 from -12 million in 2025Q1 representing a change of 83.09%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -7 million in 2025Q2 from -16 million in 2025Q1 representing a change of 59.51%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.25 in 2025Q2 from -0.25 in 2025Q1 representing a change of 52.83%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 2 million in 2025Q2 from 2 million in 2025Q1 representing a change of -11.99%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001005286 | |||
| total assets | 273702000 | 255150000 | 7.27 |
| total liabilities | 219800000 | 256992000 | -14.47 |
| total equity | 53902000 | -1842000 | 3026.28 |
| cash and cash equivalents | 8462000 | 19091000 | -55.68 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | -12050000 | 100.00 |
| total current assets | 81033000 | 99261000 | -18.36 |
| total non current assets | 172927000 | 155889000 | 10.93 |
| total current liabilities | 38872000 | 38778000 | 0.24 |
| total non current liabilities | 180928000 | 218214000 | -17.09 |
| common stock | 30000 | 30000 | 0.00 |
| retained earnings | -166523000 | -176221000 | 5.50 |
| total debt | 130360000 | 112740000 | 15.63 |
Total Assets: Total Assets increased to 274 million in 2024 from 255 million in 2023 representing a change of 7.27%. Suggesting a growth in asset holdings.
Total Liabilities: Total Liabilities decreased to 220 million in 2024 from 257 million in 2023 representing a change of -14.47%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 54 million in 2024 from -2 million in 2023 representing a change of 3026.28%. This indicates an increase in shareholders' equity.
Retained Earnings: Retained Earnings increased to -167 million in 2024 from -176 million in 2023 representing a change of 5.5%. This indicates an accumulated profits.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 8 million in 2024 from 19 million in 2023 representing a change of -55.68%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 81 million in 2024 from 99 million in 2023 representing a change of -18.36%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 39 million in 2024 from 39 million in 2023 representing a change of 0.24%. This indicates a higher short-term debt burden.
Total Debt: Total Debt increased to 130 million in 2024 from 113 million in 2023 representing a change of 15.63%. This indicates an increase in overall debt burden.
| 2025Q2 | 2025Q1 | Q/Q change % | |
|---|---|---|---|
| 0001005286 | |||
| total assets | 255386000 | 246824000 | 3.47 |
| total liabilities | 239937000 | 207321000 | 15.73 |
| total equity | 15449000 | -3938000 | 492.31 |
| cash and cash equivalents | 9455000 | 5520000 | 71.29 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 81858000 | 74183000 | 10.35 |
| total non current assets | 173528000 | 172641000 | 0.51 |
| total current liabilities | 35290000 | 40523000 | -12.91 |
| total non current liabilities | 160336000 | 166798000 | -3.87 |
| common stock | 37000 | 31000 | 19.35 |
| retained earnings | -191456000 | -182753000 | -4.76 |
| total debt | 12312000 | 136864000 | -91.00 |
Total Assets: Total Assets increased to 255 million in 2025Q2 from 247 million in 2025Q1 representing a change of 3.47%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 15 million in 2025Q2 from -4 million in 2025Q1 representing a change of 492.31%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 9 million in 2025Q2 from 6 million in 2025Q1 representing a change of 71.29%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 82 million in 2025Q2 from 74 million in 2025Q1 representing a change of 10.35%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 35 million in 2025Q2 from 41 million in 2025Q1 representing a change of -12.91%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2025Q2 from 0 in 2025Q1 representing a change of 19.35%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 12 million in 2025Q2 from 137 million in 2025Q1 representing a change of -91.0%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 240 million in 2025Q2 from 207 million in 2025Q1 representing a change of 15.73%. This indicates an increase in overall liabilities.
Retained Earnings: Retained Earnings decreased to -191 million in 2025Q2 from -183 million in 2025Q1 representing a change of -4.76%. This indicates an accumulated losses.
| 2024 | 2023 | Y/Y change % | |
|---|---|---|---|
| 0001005286 | |||
| net change in cash | -10629000 | 17448000 | -160.92 |
| operating cash flow | -217000 | -34458000 | 99.37 |
| free cash flow | -18138000 | -55221000 | 67.15 |
| capital expenditure | -17921000 | -20763000 | 13.69 |
| depreciation and amortization | 8859000 | 13508000 | -34.42 |
| deferred income tax | 163000 | 351000 | -53.56 |
| stock based compensation | 6201000 | 3612 | 171577.74 |
| accounts payables | -6676000 | 16085000 | -141.50 |
| inventory | 862000 | -13823000 | 106.24 |
| acquisitions net | 0 | 16610000 | -100.00 |
| investments in property plant and equipment | -17921000 | -20763000 | 13.69 |
| net cash used for investing activites | -17921000 | -4153000 | -331.52 |
| debt repayment | 2747000 | 3120000 | -11.96 |
| common stock issued | 724000 | 4822000 | -84.99 |
| common stock repurchased | -152000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 7509000 | 39700000 | -81.09 |
| cash at end of period | 8462000 | 19091000 | -55.68 |
| accounts receivables | -2392000 | 12194000 | -119.62 |
| cash at beginning of period | 19091000 | 1643000 | 1061.96 |
Net Change in Cash: Net Change in Cash decreased to -11 million in 2024 from 17 million in 2023 representing a change of -160.92%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to -18 million in 2024 from -21 million in 2023 representing a change of 13.69%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 6 million in 2024 from 0 million in 2023 representing a change of 171577.74%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow increased to 0 million in 2024 from -34 million in 2023 representing a change of 99.37%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -18 million in 2024 from -55 million in 2023 representing a change of 67.15%. This indicates an increase in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables decreased to 7 million in 2024 from 16 million in 2023 representing a change of -141.5%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -2 million in 2024 from 12 million in 2023 representing a change of -119.62%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
| 2025Q2 | 2025Q1 | Q/Q change % | |
|---|---|---|---|
| 0001005286 | |||
| operating cash flow | -6110000 | -643000 | -850.23 |
| free cash flow | -8580000 | -4035000 | -112.64 |
| capital expenditure | -2470000 | -3392000 | 27.18 |
| depreciation and amortization | 2044000 | 1993000 | 2.56 |
| deferred income tax | 9000 | -100000 | 109.00 |
| stock based compensation | 3372000 | 2419000 | 39.40 |
| accounts receivables | 0 | 6019000 | -100.00 |
| accounts payables | -2837000 | 3628000 | -178.20 |
| inventory | 0 | -1663000 | 100.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -2470000 | -3392000 | 27.18 |
| net cash used for investing activites | -2470000 | -3392000 | 27.18 |
| debt repayment | -10940000 | 1681000 | -750.80 |
| common stock issued | 0 | 1000 | -100.00 |
| common stock repurchased | 0 | -589000 | 100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 12515000 | 1093000 | 1045.01 |
| net change in cash | 3935000 | -2942000 | 233.75 |
| cash at end of period | 9455000 | 5520000 | 71.29 |
| cash at beginning of period | 5520000 | 8462000 | -34.77 |
Net Change in Cash: Net Change in Cash increased to 4 million in 2025Q2 from -3 million in 2025Q1 representing a change of 233.75%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2025Q2 from 4 million in 2025Q1 representing a change of -178.2%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 0 million in 2025Q2 from 6 million in 2025Q1 representing a change of -100.0%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to -6 million in 2025Q2 from -1 million in 2025Q1 representing a change of -850.23%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -9 million in 2025Q2 from -4 million in 2025Q1 representing a change of -112.64%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -2 million in 2025Q2 from -3 million in 2025Q1 representing a change of 27.18%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to 0 million in 2025Q2 from 0 million in 2025Q1 representing a change of 109.0%. This indicates that the company's tax liability for future periods has increased.
Stock-Based Compensation: Stock-Based Compensation increased to 3 million in 2025Q2 from 2 million in 2025Q1 representing a change of 39.4%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q2 2025 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2024-05-26 | 2023-05-28 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 4.21 | 3.45 | 22.10 |
| net income per share | 0.39 | -3.41 | 111.56 |
| operating cash flow per share | -0.01 | -1.15 | 99.38 |
| free cash flow per share | -0.6 | -1.84 | 67.71 |
| cash per share | 0.28 | 0.64 | -56.43 |
| book value per share | 1.77 | -0.06 | 2976.73 |
| tangible book value per share | 1.18 | -0.67 | 276.75 |
| shareholders equity per share | 1.77 | -0.06 | 2976.73 |
| interest debt per share | 4.87 | 4.37 | 11.47 |
| market cap | 171263880 | 237866520 | -28.00 |
| enterprise value | 293161880 | 331515520 | -11.57 |
| pe ratio | 14.26 | -2.33 | 712.48 |
| price to sales ratio | 1.34 | 2.3 | -42.03 |
| pocfratio | -789.23 | -6.9 | -11333.07 |
| pfcf ratio | -9.44 | -4.31 | -119.20 |
| pb ratio | 3.18 | -129.13 | 102.46 |
| ptb ratio | 3.18 | -129.13 | 102.46 |
| ev to sales | 2.29 | 3.21 | -28.80 |
| enterprise value over ebitda | 8.23 | -9.21 | 189.36 |
| ev to operating cash flow | -1350.98 | -9.62 | -13942.16 |
| ev to free cash flow | -16.16 | -6.0 | -169.23 |
| earnings yield | 0.07 | -0.43 | 116.33 |
| free cash flow yield | -0.11 | -0.23 | 54.38 |
| debt to equity | 2.42 | -61.21 | 103.95 |
| debt to assets | 0.48 | 0.44 | 7.79 |
| net debt to ebitda | 3.42 | -2.6 | 231.54 |
| current ratio | 2.08 | 2.56 | -18.56 |
| interest coverage | 0.52 | -1.43 | 135.96 |
| income quality | -0.02 | 0.34 | -106.90 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0.42 | -100.00 |
| research and ddevelopement to revenue | 0.07 | 0.08 | -16.21 |
| intangibles to total assets | 0.07 | 0.07 | -6.78 |
| capex to operating cash flow | -82.59 | -0.6 | -13605.74 |
| capex to revenue | 0.14 | 0.2 | -30.51 |
| capex to depreciation | 2.02 | 1.54 | 31.61 |
| stock based compensation to revenue | 0.05 | 0.0 | 138125.87 |
| graham number | 3.96 | 2.17 | 82.33 |
| roic | 0.04 | -0.12 | 134.65 |
| return on tangible assets | 0.05 | -0.43 | 110.90 |
| graham net net | -5.51 | -6.46 | 14.63 |
| working capital | 42161000 | 60483000 | -30.29 |
| tangible asset value | 35821000 | -19923000 | 279.80 |
| net current asset value | -138767000 | -157731000 | 12.02 |
| invested capital | 211282000 | 213157000 | -0.88 |
| average receivables | 30088500 | 33669000 | -10.63 |
| average payables | 19215500 | 17524500 | 9.65 |
| average inventory | 42681500 | 56175000 | -24.02 |
| days sales outstanding | 88.65 | 102.58 | -13.58 |
| days payables outstanding | 68.99 | 106.16 | -35.01 |
| days of inventory on hand | 168.87 | 218.03 | -22.55 |
| receivables turnover | 4.12 | 3.56 | 15.71 |
| payables turnover | 5.29 | 3.44 | 53.86 |
| inventory turnover | 2.16 | 1.67 | 29.11 |
| roe | 0.22 | 55.48 | -99.60 |
| capex per share | 0.59 | 0.69 | -15.15 |
ROE: Return on Equity (ROE) decreased to 0.22 on 2024-05-26 from 55.48 on 2023-05-28, representing a change of -99.60%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Current Ratio: Current Ratio decreased to 2.08 on 2024-05-26 from 2.56 on 2023-05-28, representing a change of -18.56%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 14.26 on 2024-05-26 from -2.33 on 2023-05-28, representing a change of 712.48%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 2.42 on 2024-05-26 from -61.21 on 2023-05-28, representing a change of 103.95%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. A ratio of 2.0 or higher is usually considered risky.
| 2024-11-24 Q2 | 2024-08-25 Q1 | Q/Q change % | |
|---|---|---|---|
| LFCR | |||
| calendar year | 2025 | 2025 | NaN |
| revenue per share | 0.95 | 0.8 | 18.37 |
| net income per share | -0.19 | -0.53 | 63.64 |
| operating cash flow per share | -0.18 | -0.02 | -753.31 |
| free cash flow per share | -0.25 | -0.13 | -90.95 |
| cash per share | 0.28 | 0.18 | 53.81 |
| book value per share | 0.45 | 1.28 | -64.88 |
| tangible book value per share | -0.08 | 0.69 | -111.03 |
| shareholders equity per share | 0.45 | -0.13 | 452.29 |
| interest debt per share | 0.52 | 4.61 | -88.78 |
| market cap | 256330501.22 | 195625404.28 | 31.03 |
| enterprise value | 259187501.22 | 326969404.28 | -20.73 |
| pe ratio | -9.75 | -3.01 | -223.64 |
| price to sales ratio | 7.87 | 7.92 | -0.59 |
| pocfratio | -41.95 | -304.24 | 86.21 |
| pfcf ratio | -29.88 | -48.48 | 38.38 |
| pb ratio | 16.59 | -49.68 | 133.40 |
| ptb ratio | 16.59 | -49.68 | 133.40 |
| ev to sales | 7.96 | 13.23 | -39.86 |
| enterprise value over ebitda | 264.21 | -36.76 | 818.68 |
| ev to operating cash flow | -42.42 | -508.51 | 91.66 |
| ev to free cash flow | -30.21 | -81.03 | 62.72 |
| earnings yield | -0.03 | -0.08 | 69.10 |
| free cash flow yield | -0.03 | -0.02 | -62.28 |
| debt to equity | 0.8 | -34.75 | 102.29 |
| debt to assets | 0.05 | 0.55 | -91.31 |
| net debt to ebitda | 2.91 | -14.77 | 119.72 |
| current ratio | 2.32 | 1.83 | 26.71 |
| interest coverage | -0.36 | -2.16 | 83.39 |
| income quality | 0.93 | 0.04 | 2247.02 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.06 | 0.09 | -33.23 |
| intangibles to total assets | 0.07 | 0.07 | -3.35 |
| capex to operating cash flow | -0.4 | -5.28 | 92.34 |
| capex to revenue | 0.08 | 0.14 | -44.76 |
| capex to depreciation | 1.21 | 1.7 | -29.00 |
| stock based compensation to revenue | 0.1 | 0.1 | 5.75 |
| graham number | 1.39 | 1.23 | 13.17 |
| roic | -0.01 | -0.05 | 83.99 |
| return on tangible assets | -0.03 | -0.07 | 60.97 |
| graham net net | -5.7 | -5.25 | -8.42 |
| working capital | 46568000 | 33660000 | 38.35 |
| tangible asset value | -2632000 | 21422000 | -112.29 |
| net current asset value | -158079000 | -133138000 | -18.73 |
| invested capital | 217529000 | 202870000 | 7.23 |
| average receivables | 22661000 | 28149000 | -19.50 |
| average payables | 16488500 | 17172000 | -3.98 |
| average inventory | 40428000 | 40810500 | -0.94 |
| days sales outstanding | 55.76 | 91.6 | -39.12 |
| days payables outstanding | 62.71 | 83.91 | -25.26 |
| days of inventory on hand | 164.3 | 194.0 | -15.31 |
| receivables turnover | 1.61 | 0.98 | 64.27 |
| payables turnover | 1.44 | 1.07 | 33.80 |
| inventory turnover | 0.55 | 0.46 | 18.08 |
| roe | -0.43 | 4.12 | -110.32 |
| capex per share | 0.07 | 0.11 | -34.61 |
ROE: Return on Equity (ROE) decreased to -0.43 on 2024-11-24 Q2 from 4.12 on 2024-08-25 Q1, representing a change of -110.32%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -9.75 on 2024-11-24 Q2 from -3.01 on 2024-08-25 Q1, representing a change of -223.64%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 2.32 on 2024-11-24 Q2 from 1.83 on 2024-08-25 Q1, representing a change of 26.71%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.80 on 2024-11-24 Q2 from -34.75 on 2024-08-25 Q1, representing a change of 102.29%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-17 17:24:00
Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
Sentiment: Positive
Publish Date: 2025-01-14 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-13 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-12 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-10 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-09 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-08 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-07 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-07 09:00:00
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue
Sentiment: Neutral
Publish Date: 2025-01-06 16:05:00
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
Sentiment: Positive
Publish Date: 2025-01-06 10:00:00
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-05 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2025-01-03 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Negative
Publish Date: 2025-01-02 18:26:18
Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.06 per share a year ago.
Sentiment: Positive
Publish Date: 2025-01-02 18:19:12
Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q2 2025 Earnings Conference Call January 2, 2025 4:00 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - President & CEO Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jacob Johnson - Stephens Michael Petusky - Barrington Research Operator Good afternoon, and thank you for joining Lifecore's Financial 2025 Second Quarter Earnings Call. During the call, all participants will be in a listen-only mode.
Sentiment: Positive
Publish Date: 2025-01-02 16:05:00
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers --
Sentiment: Positive
Publish Date: 2024-12-31 10:00:00
NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2024-12-30 15:30:00
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2024-12-29 10:00:00
NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Sentiment: Positive
Publish Date: 2024-12-24 10:00:00
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
